LEUVEN, Belgium, May 16, 2013 /PRNewswire/ --
- JETREA ® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million
- Phase IIa study evaluating JETREA ® in wet AMD patients shows 24% VMA resolution rate for JETREA ® treated patients, versus 12% for sham injection. This positive trend and safety profile warrant further larger studies to confirm clinical benefits
- Company Cash position: over €200 million
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today issued a business and financial update ending 30 April, 2013.
During 2013, ThromboGenics delivered a number of key corporate milestones, the most important of which was the launch of JETREA ® (ocriplasmin) in the US on 14 January via its own commercial organization. ThromboGenics' partner outside the US, Alcon, launched JETREA ® in the UK and Germany after its approval by the European Commission in March 2013. The EU approval and the launch of JETREA ® in the UK led to ThromboGenics receiving two equal milestones from Alcon amounting to a total of €90 million.
Following these launches, patients and physicians in the US and the EU now have access to the first pharmacological treatment for the sight-threatening condition known as symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT) respectively. The launches of JETREA ® complete ThromboGenics' transformation into an integrated company with operations in R&D through to full-scale commercialization.ThromboGenics and Alcon are now focused on generating greater awareness of the drug and driving JETREA ® adoption and revenues in the US and Europe. Highlights (including post-period events):